Abstract
The diagnosis and immediate initiation of reperfusion therapy in patients with acute ST-elevation myocardial infarction (STEMI) are based on results of the standard 12-lead electrocardiogram. Because the appearance of cardiac markers of myocardial injury in the blood is delayed relative to the onset of symptom, cardiac markers are neither helpful for early diagnosis nor should their results be awaited before initiation of reperfusion therapy. Nevertheless, there are four important reasons to measure cardiac markers of necrosis in patients with STEMI: (1) confirmation of diagnosis, (2) monitoring of efficiency of reperfusion, (3) assessment of risk, and (4) infarct sizing.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44:671–719.
Chan CP, Sanderson JE, Glatz JF, Cheng WS, Hempel A, Renneberg R. A superior early myocardial infarction marker: human heart-type fatty acid-binding protein. Z Kardiol 2004;93:388–397.
Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on standardization of clinical nomenclature. Circulation 1979;59:607–609.
The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21: 1502–1513.
Katus HA, Remppis A, Neumann FJ, et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation 1991;83:902–912.
Katus HA, Remppis A, Scheffold T, et al. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol 1991; 67:1360–1367.
Krucoff MW, Croll MA, Pope JE, et al., for the TAMI 7 study. Performance of a noninvasive method for real-time detection of failed myocardial reperfusion. Circulation 1993;88:437–446.
Langer A, Krucoff MW, Klootwijk P, et al. Noninvasive assessment of speed and stability of infarctrelated artery reperfusion: results of the GUSTO ST segment monitoring study: global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries. J Am Coll Cardiol 1995;25: 1552–1557.
Katus HA, Diederich KW, Scheffold T, Uellner M, Schwarz F, Kübler W. Non-invasive assessment of infarct reperfusion: the predictive power of the time to peak value of myoglobin, CKMB, and CK in serum. Eur Heart J 1988;9:619–624.
Apple FS. Value of soluble markers in the diagnosis of reperfusion. In: Kaski JC, Holt DW, eds. Developments in Cardiovascular Medicine: Myocardial Damage—Early Detection by Novel Biochemical Markers. Kluwer Academic, Dordrecht, The Netherlands, 1998, pp. 149–157.
Stewart JT, French JK, Theroux P, et al. Early non-invasive identification of failed reperfusion after intravenous thrombolytic therapy in acute myocardial infarction. J Am Coll Cardiol 1998;31:1499–1505.
Tanasijevic MJ, Cannon CP, Antman EM, et al., for the TIMI 10B Investigators. Myoglobin, creatine kinase MB and cardiac troponin I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction. J Am Coll Cardiol 1999;34:739–747.
Apple FS, Henry TD, Berger CR, Landt YA. Early monitoring of serum cardiac troponin I for assessment of coronary reperfusion following thrombolytic therapy. Am J Clin Pathol 1996;105:6–10.
Zabel M, Hohnloser SH, Koster W, Prinz M, Kasper W, Just H. Analysis of creatine kinase, CK-MB, myoglobin, and troponin T time-activity curves for early assessment of coronary artery reperfusion after intravenous thrombolysis. Circulation 1993;87:1542–1550.
Wu K, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998;97:765–772.
Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992;85:1699–1705.
Laperche T, Steg PG, Benessiano J, et al. Patterns of myoglobin and MM creatine kinase isoforms release early after intravenous thrombolysis or direct percutaneous transluminal coronary angioplasty for acute myocardial infarction, and implications for the early noninvasive diagnosis of reperfusion. Am J Cardiol 1992;70:1129–1134.
Frostfeldt G, Gustafsson G, Lindahl B, Nygren A, Venge P, Wallentin L. Possible reasons for the prognostic value of troponin-T on admission in patients with ST-elevation myocardial infarction. Coron Artery Dis 2001;12:227–237.
Lehrke S, Katus HA, Giannitsis E. Admission troponin T predicts benefits abciximab administration after successful primary percutaneous intervention for acute ST-segment myocardial infarction. Thromb Haemost 2004;92:1214–1220.
Wong GC, Morrow DA, Murphy S, et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation 2002;106:202–207.
Kurowski V, Hartmann F, Killermann DP, et al. Prognostic significance of admission cardiac troponin T in patients treated successfully with direct percutaneous interventions for acute ST-segment elevation myocardial infarction. Crit Care Med 2002;30:2229–2235.
Topol EJ; GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905–1914.
Ohman EM, Armstrong PW, White HD, for the GUSTO-III Investigators. Risk stratification with a point-of care cardiac troponin T test in acute myocardial infarction. Am J Cardiol 1999;84:1281–1286.
Stubbs P, Collinson P, Moseley D, et al. Prognostic significance of admission troponin T concentrations in patients with myocardial infarction. Circulation 1996;94:1291–1297.
Giannitsis E, Lehrke S, Wiegand U, et al. Risk stratification in patients with inferior acute myocardial infarction treated by percutaneous coronary interventions—the role of admission troponin T. Circulation 2000;102:2038–2044.
Matetzky S, Sharir T, Domingo M, et al. Elevated troponin I level on admission is associated with adverse outcome of primary angioplasty in acute myocardial infarction. Circulation 2000;102:1611–1616.
Bjorklund E, Lindahl B, Johanson P, et al. Admission Troponin T and measurement of ST-segment resolution at 60 min improve early risk stratification in ST-elevation myocardial infarction. Eur Heart J 2004; 25:113–120.
Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985;71:699–708.
Gibbons RJ, Valeti US, Araoz PA, Jaffe AS. The quantification of infarct size. J Am Coll Cardiol 2004; 44:1533–1542.
Grande P, Christiansen C, Alstrup K. Comparison of ASAT, CK, CK-MB, and LD for the estimation of acute myocardial infarct size in man. Clin Chim Acta 1983;128:329–335.
Al Saady NM, Camm AJ. New soluble markers for assessment of infarct size. In: Kaski JC, Holt DW, eds. Myocardial Damage: Early Detection by Novel Biochemical Markers. Kluwer Academic, Dordrecht, The Netherlands, 1998, pp. 137–148.
Smith JL, Ambos HD, Gold HK, et al. Enzymatic estimation of myocardial infarct size when early creatine kinase values are not available. Am J Cardiol 1983;51:1294–1300.
Vatner SF, Baig H, Manders WT, Maroko PR. Effects of coronary artery reperfusion on myocardial infarct size calculated from creatine kinase. J Clin Investig 1977;61:1048–1056.
Remppis A, Ehlermann P, Giannitsis E, et al. Cardiac troponin T levels at 96 hours reflect myocardial infarct size: a pathoanatomical study. Cardiology 2000;93:249–253.
Licka M, Zimmermann R, Zehelein J, Dengler TJ, Katus HA, Kubler W. Troponin T concentrations 72 athours after myocardial infarction as a serological estimate of infarct size. Heart 2002;87:520–524.
Panteghini M, Cuccia C, Bonetti G, Giubbini R, Pagani F, Bonini E. Single-point cardiac troponin T at coronary care unit discharge after myocardial infarction correlates with infarct size and ejection fraction. Clin Chem 2002;48:1432–1436.
Korosoglou G, Labadze N, Hansen A, et al. Usefulness of real-time myocardial perfusion imaging in the evaluation of patients with first time chest pain. Am J Cardiol 2004;94:1225–1231.
Ingkanisorn WP, Rhoads KL, Aletras AH, Kellman P, Arai AE. Gadolinium delayed enhancement cardiovascular magnetic resonance correlates with clinical measures of myocardial infarction. J Am Coll Cardiol 2004;43:2253–2259.
Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001;103:2780–2783.
Wagner A, Mahrholdt H, Holly TA, et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet 2003;361:374–379.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Giannitsis, E., Katus, H.A. (2006). Biomarkers of Necrosis for Risk Assessment and Management of ST-Elevation Myocardial Infarction. In: Morrow, D.A. (eds) Cardiovascular Biomarkers. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-59745-051-5_6
Download citation
DOI: https://doi.org/10.1007/978-1-59745-051-5_6
Publisher Name: Humana Press
Print ISBN: 978-1-58829-526-2
Online ISBN: 978-1-59745-051-5
eBook Packages: MedicineMedicine (R0)